Browse the evidence

The potential effect of sitagliptin on blood glucose was lost by month 6 after treatment discontinuation.

This suggests that continuous treatment may be necessary to maintain glycemic control.

Anti-obesity vaccines are primarily in preclinical to Phase II stages, with candidates like ghrelin vaccines showing up to 15% reduced weight gain in preclinical models.

Ghrelin vaccines may be a promising avenue for reducing weight gain in future therapies.

Somatostatin vaccines achieved 10–13% weight loss in mice.

Somatostatin vaccines may provide a viable option for weight loss in future treatments.

Amylin receptor activation has emerged as a promising drug target for the treatment of diabetes and obesity.

Practitioners should consider amylin receptor activators as a potential treatment option for obesity and diabetes.

SGLT2i sind etabliert zur Reduktion von Herzinsuffizienzhospitalisierungen und Nierenendpunkten über das gesamte Herzinsuffizienzspektrum.

Clinicians should utilize SGLT2 inhibitors for managing heart failure and kidney disease.

The EndoCompass project identifies strategic research priorities in endocrine science to address critical hormone-related health challenges.

Practitioners should focus on the identified research priorities to improve hormone health.

Current evidence does not support a single dominant mechanism for the efficacy of GLP-1 receptor agonists.

Practitioners should consider multiple factors influencing the effectiveness of GLP-1 receptor agonists.

The DRL model decreased the time-to-therapeutic-dose by 20% in simulations.

Using a DRL agent can expedite achieving therapeutic doses for patients.

High-dose vitamin D treatment has no significant effect on β-cell function, insulin sensitivity, or glucose homeostasis in subjects with abnormal glucose tolerance.

Practitioners should reconsider the use of high-dose vitamin D for improving glucose metabolism in at-risk patients.

Higher circulating levels of estradiol are associated with an increased risk of breast cancer in postmenopausal women (multivariate RR = 1.91; 95% CI = 1.06-3.46).

Practitioners should consider monitoring estradiol levels in postmenopausal women as a potential risk factor for breast cancer.

Higher levels of estrone, estrone sulfate, and dehydroepiandrosterone sulfate are also associated with increased breast cancer risk.

Practitioners should be aware of the potential risks associated with elevated levels of estrone, estrone sulfate, and dehydroepiandrosterone sulfate in postmenopausal women.

No substantial associations were found with percent free or percent bioavailable estradiol, androstenedione, testosterone, or dehydroepiandrosterone.

Practitioners should note that not all hormone levels are associated with breast cancer risk, particularly those mentioned.

Circulating cortisol concentrations are somewhat lower in obese than in nonobese community-dwelling men.

Practitioners should consider that lower cortisol levels may be associated with obesity in middle-aged and older men.

T2 cortisol concentrations were not associated with change in body composition over time.

Practitioners should note that changes in cortisol levels do not predict changes in body composition.

There were no differences in fasting plasma leptin concentrations between insulin-sensitive and insulin-resistant subjects after adjusting for percent body fat.

Insulin resistance does not appear to influence leptin levels when body fat is controlled for.

Plasma leptin concentrations did not change in response to insulin in either the insulin-sensitive or insulin-resistant subjects.

Insulin does not appear to influence leptin levels acutely, which may have implications for metabolic regulation.

Testosterone treatment further shortens the QTc interval in males with Klinefelter syndrome.

Testosterone therapy in males with KS may require monitoring of cardiac function due to its effects on QTc interval.

Plasma adiponectin concentrations are not correlated with 24-hour respiratory quotient (RQ) in humans.

Adiponectin levels may not be a useful marker for assessing fat oxidation in healthy individuals.

Physiological concentrations of fasting plasma adiponectin do not play a role in the regulation of whole-body fat oxidation or energy expenditure in resting conditions.

Adiponectin may not be a target for increasing fat oxidation or energy expenditure in healthy individuals.

Existing pharmaceuticals and bariatric surgeries have limited efficacy and side effects.

Awareness of the limitations of current treatments can guide practitioners in exploring new options.

Estradiol levels were not associated with cognitive function in either sex.

Practitioners should note that estradiol does not appear to influence cognitive function in this population.

Total testosterone levels were not associated with cognitive function in women.

Practitioners should be aware that testosterone does not influence cognitive function in women with T2DM.

Viscosity seems to have no effect on active CCK and glucagon-like peptide-1.

Practitioners should note that the viscosity of chocolate does not affect CCK or GLP-1 levels.

Neither circulating plasma IL-6 nor skeletal muscle IL-6 mRNA are predictors of insulin resistance in patients with type 2 diabetes.

Practitioners should not rely on IL-6 levels as indicators of insulin resistance in type 2 diabetes.